• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8/19/24 5:00:40 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BGXX alert in real time by email
    false 0001886799 0001886799 2024-08-13 2024-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported) August 13, 2024

     

    BRIGHT GREEN CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41395   83-4600841

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    1033 George Hanosh Boulevard

    Grants, NM 87020

    (Address of principal executive offices and zip code)

     

    (833) 658-1799

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   BGXX   Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On June 5, 2022, Bright Green Corporation (the “Company”) and LDS Capital LLC (“LDS”), whose managing member is Lynn Stockwell, Chair of the Company’s board of directors, entered into an unsecured line of credit in the form of a note, which provided that the Company could borrow up to $5 million from LDS, which amount was increased to $15 million on November 14, 2022 (as amended, the “Note”). On January 31, 2023, LDS assigned the Note to Ms. Stockwell (the “Lender”).

     

    On September 1, 2023, the Company and the Lender entered into an agreement pursuant to which, in consideration for the cancellation and full satisfaction of all amounts of principal, interest and other costs under the Note as of August 31, 2023, the Company issued to the Lender (i) 2,827,960 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), representing a conversion of outstanding principal at $1.15 per Share, and (ii) warrants representing a conversion of outstanding principal at $0.13 per warrant (the “Warrants”) to purchase up to 2,827,960 shares of Common Stock at a price of $3.00 per share.

     

    On August 19, 2024, the board of directors of the Company approved an amendment and restatement to the Note (the “Secured Note”), pursuant to which, among other things, upon the Lender making a new advance in the principal amount of at least $3,500,000 under the terms of the Secured Note (the “Required Funding”), all obligations due under the Secured Note shall be secured by (i) a first lien mortgage on the Company’s fee interest in the real property and improvements thereon, including, without limitation, the land, buildings, fixtures, equipment and machinery located at 1033 George Hanosh Blvd, Grants, NM 87020 (the “Property”) and a first priority assignment of leases and rents, (ii) a first priority security interest in all accounts receivable of Company, (iii) an assignment of all contracts, licenses, permits, plans, specifications and other documentation with respect to the Property, and (iv) such other collateral as is customary for a loan of this type, including additional real property if the acquisition of such property occurs while this Secured Note is outstanding. As of the date hereof, the Lender has not provided the Required Funding and the Company cannot currently anticipate when the Required Funding will be made.

     

    The Secured Note also provides for a conversion feature pursuant to which Lender may, at her discretion, convert the outstanding principal and interest balance of the Secured Note into (i) shares of the Company’s Common Stock at a price of $1.15 per share (the “Shares”) and (ii) warrants at a price of $0.13 per warrant, which warrants shall be exercisable into shares of the Company’s Common Stock at an exercise price of $3.00 per share (the “Warrant Shares”). Each of the price per Share and exercise price per Warrant Share represents a premium to the trading price of the Common Stock on the Nasdaq Capital Market.

     

    Additionally, in connection with the entry into the Secured Note, the Company and the Lender entered into an amendment to the Warrant (the “Warrant Amendment”), pursuant to which the Termination Date (as defined therein) shall mean the earlier of (i) the date that is 45 days after the date on which the closing price of the Company’s Common Stock on the Trading Market (as defined therein) equals or exceeds $3.00 per share, and (ii) August 31, 2027. The Warrant Amendment shall only become effective upon receipt by the Company of the Required Funding.

     

    The foregoing descriptions of the Warrant Amendment and the Secured Note do not purport to be complete and are qualified in their entirety by the full text of the Warrant Amendment and the Secured Note, which are filed as Exhibit 4.1 and Exhibit 10.1 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information contained above under Item 1.01 is hereby incorporated by reference into this Item 2.03.

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On August 16, 2023, the Company received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) which requires a minimum bid price of at least $1.00 per share because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days. The Company was given until February 12, 2024 to regain compliance with the Bid Price Rule. On February 13, 2024, the Company received notice from Nasdaq that the Company had been granted an additional 180-day grace period, or until August 12, 2024, to regain compliance with the Bid Price Rule.

     

    The Company did not regain compliance with the Bid Price Rule by August 12, 2024. On August 13, 2024, the Company received from Nasdaq a delisting determination letter (the “Delisting Determination Letter”). The Delisting Determination Letter states that unless the Company requests a hearing before a Nasdaq Hearing Panel (“Panel”) to appeal Nasdaq’s delisting determination by August 20, 2024, trading of the Company’s common stock on the Nasdaq Capital Market will be suspended at the opening of trading on August 22, 2024, and the Company’s common stock will be delisted from Nasdaq. Nasdaq notified the Company that it will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the Company’s common stock from listing and registration on Nasdaq.

     

    The Company has submitted a hearing request to appeal the delisting determination to a Panel. The Company’s hearing request will stay the suspension of the Company’s common stock and the filing of the Form 25-NSE pending the Panel’s decision. There can be no assurance that the Panel will grant the Company’s request for continued listing.

     

    If the Company’s hearing request for continued listing is not granted, the Company’s common stock will be traded on the OTC Pink Sheets and the Company will seek to establish relationships with market makers to provide additional trading opportunities in the Company’s common stock. However, there can be no assurance that a market for the Company’s shares will continue or develop.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits

     

    Exhibit No.   Description
    4.1   Warrant Amendment, dated August as of August 19, 2024
    10.1   Secured Amended and Restated Line of Credit Note, dated as of August 19, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 19, 2024 Bright Green Corporation
       
      By: /s/ Gurvinder Singh
        Gurvinder Singh
        Chief Executive Officer

     

     

     

     

    Get the next $BGXX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGXX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Elmasri Saleem sold $4,951 worth of shares (25,942 units at $0.19), decreasing direct ownership by 2% to 1,103,476 units (SEC Form 4)

    4 - Bright Green Corp (0001886799) (Issuer)

    9/11/24 4:05:11 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Elmasri Saleem sold $14,313 worth of shares (71,809 units at $0.20), decreasing direct ownership by 6% to 1,129,418 units (SEC Form 4)

    4 - Bright Green Corp (0001886799) (Issuer)

    9/10/24 4:05:08 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: Chief Executive Officer Singh Gurvinder was granted 5,500,000 shares (SEC Form 4)

    4/A - Bright Green Corp (0001886799) (Issuer)

    9/9/24 4:05:32 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    $BGXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys' Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith

    Court Found No Wrongdoing by Lynn Stockwell; Judgment Imposed Joint and Several Liability Due to Counsel's Failure Cibola County, New Mexico, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXXQ) and its Chief Executive Officer, Lynn Stockwell, today announced the filing of a landmark lawsuit seeking damages in excess of $3 billion against Rodey Law Firm and Attorneys' Liability Assurance Society (ALAS). The complaint, filed in the Thirteenth Judicial District Court of New Mexico, alleges legal malpractice, breach of contract, and bad faith breach of fiduciary duty. The underlying litigation resulted in findings of no wrongdoing by Lynn Stockwell. Despite this, the court

    1/8/26 9:00:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation "BGXXQ" Q and A

    Fort Lauderdale, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PharmAGRI Capital Partners today announced its strategic focus on capturing a $10 billion total addressable market (TAM) in federal procurement of plant-based prescription drugs currently sourced from foreign manufacturers. This segment, while modest in size compared to the broader pharmaceutical industry, represents a critical opportunity to restore control, compliance, and domestic production with a fair transparent pricing model. CEO Statement: "The $10B TAM is not about volume—it's about control. Federal agencies already procure these drugs, often from foreign sources. Our goal is to ensure they contract with a sovereign platfor

    9/16/25 3:14:00 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman

    Tesla Robotics to Power Sovereign "Seed to Syringe" Pharmaceutical Infrastructure Fort Lauderdale, FL, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) has announced its merger with PharmAGRI Capital Partners, a federally aligned pharmaceutical infrastructure platform architected to restore U.S. drug manufacturing sovereignty. The transaction consolidates BGXX's DEA registrations, Board of Pharmacy licensure, audited financials, and Nasdaq history into PharmAGRI under a court-supervised restructuring plan filed in the District of New Mexico. Effective immediately, Lynn Stockwell has been appointed Chief Executive Officer and Chairwoman of PharmAGRI. Ms. Stockwell wi

    9/15/25 8:02:14 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    $BGXX
    SEC Filings

    View All

    SEC Form 25-NSE filed by Bright Green Corporation

    25-NSE - Bright Green Corp (0001886799) (Subject)

    3/21/25 11:19:49 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Bright Green Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bright Green Corp (0001886799) (Filer)

    3/21/25 9:15:14 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits

    8-K - Bright Green Corp (0001886799) (Filer)

    2/27/25 4:05:24 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    $BGXX
    Leadership Updates

    Live Leadership Updates

    View All

    (Updated) U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

    Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

    1/14/24 10:00:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

    Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

    10/3/23 11:11:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Bright Green Announces First Quarter 2023 Financial Update and Milestone Progress

    Bright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval. Commencement of its fundamental capital raise of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company's significant progress against its strategic plan. Company has raised short-term working Capital of $5.26m to commence its operations as it looks to capitalize on its historic DEA Registration in Q2 2023 and beyond. GRANTS, N.M., May 24, 2023 (GLOBE NEWSWIRE) -- Brig

    5/24/23 8:00:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    $BGXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Bright Green Corporation (Amendment)

    SC 13D/A - Bright Green Corp (0001886799) (Subject)

    9/6/23 5:19:19 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Bright Green Corporation

    SC 13D - Bright Green Corp (0001886799) (Subject)

    6/15/23 4:30:21 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Bright Green Corporation (Amendment)

    SC 13G/A - Bright Green Corp (0001886799) (Subject)

    6/12/23 5:28:12 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care